close

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in the United States. Its lead product candidate includes prGCD, a proprietary plant cell expressed recombinant Glucocerebrosidase enzyme for the treatment of Gaucher disease, which is in Phase III clinical trial. The company also develops PRX-102, a proprietary alpha Galactosidase enzyme for the treatment of Fabry disease, a genetic lysosomal storage disorder in humans, the symptoms of which involve the accumulation of lipids in the cells of the kidneys, heart, and other organs; a proprietary plant cell-based acetylcholinestrase and its molecular variants for use in various therapeutic and prophylactic indications, including a Biodefense program; and an organophosphate-based pesticide treatment program. Protalix BioTherapeutics, Inc. has strategic collaboration with Teva Pharmaceutical Industries, Ltd. for the development and manufacturing of two proteins using the company's ProCellEx protein expression system; and Yeda Research and Development Company Limited to design Glucocerebrosidase for the treatment of Gaucher disease, as well as has a licensing agreement with Icon Genetics AG to license Icon's amplification technology for utilization in the expression of its products. The company was founded in 1993 and is based in Carmiel, Israel.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	5.78
Volume	299390
Volume Avg	251106
52 Week High	7.28
52 Week Low	4.06
PE	N/A
PE (group average)	N/A
EPS Year	-0.43
EPS change Q/Q	-45.45%
EPS change Q/Q Yr ago	-40%
EPS change Q/Q next Q est	-40%
EPS change Y/Y	-37.5%
REV change Q/Q	-11.76%
REV change Q/Q Yr ago	650%
EPS next Q est	-0.10
EPS next Y est	0.03
Divident Annual	0.00
Dividend Yield	0%